StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI)

StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note issued to investors on Monday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright boosted their target price on shares of CASI Pharmaceuticals from $10.00 to $12.00 and gave the company a buy […]

Leave a Reply

Your email address will not be published.

Previous post Vera Therapeutics (NASDAQ:VERA) Coverage Initiated at Cantor Fitzgerald
Next post United States Steel (NYSE:X) Now Covered by Analysts at StockNews.com